A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

The purpose of this study is to confirm the efficacy and safety of perampanel compared to placebo in patients with refractory partial-onset seizures

Study Overview

• Status: Completed
• Conditions: Partial-onset Seizures
• Intervention / Treatment: Drug: Perampanel; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 940
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Bedford Park, Australia
    • Facility #1
  • Camperdown, Australia
    • Facility #1
  • Clayton, Australia
    • Facility #1
  • Fitzroy, Australia
    • Facility #1
  • Heidelberg, Australia
    • Facility #1
  • Melbourne, Australia
    • Facility #1
  • Randwick, Australia
    • Facility #1
• China
  • Beijing
    • Beijing, Beijing, China
      • Facility #1
  • Chongqing
    • Chongqing, Chongqing, China
      • Facility #1
  • Fujian
    • Xiamen, Fujian, China
      • Facility #1
  • Guangdong
    • Guangzhou, Guangdong, China
      • Facility #1
    • Guangzhou, Guangdong, China
      • Facility #2
  • Heilongjiang
    • Harbin, Heilongjiang, China
      • Facility #1
  • Jilin
    • Changchun, Jilin, China
      • Facility #1
  • Shaanxi
    • Xi'an, Shaanxi, China
      • Facility #1
    • Xi'an, Shaanxi, China
      • Facility #2
    • Xi'an, Shaanxi, China
      • Facility #3
  • Shandong
    • Jinan, Shandong, China
      • Facility #1
    • Jinan, Shandong, China
      • Facility #2
    • Qingdao, Shandong, China
      • Facility #1
  • Shanghai
    • Shanghai, Shanghai, China
      • Facility #1
    • Shanghai, Shanghai, China
      • Facility #2
    • Shanghai, Shanghai, China
      • Facility #3
  • Shanxi
    • Taiyuan, Shanxi, China
      • Facility #1
  • Sichuan
    • Chengdu, Sichuan, China
      • Facility #1
    • Chengdu, Sichuan, China
      • Facility #2
  • Tianjin
    • Tianjin, Tianjin, China
      • Facility #1
  • Yunnan
    • Kunming, Yunnan, China
      • Facility #1
  • Zhejiang
    • Wenzhou, Zhejiang, China
      • Facility #1
• Japan
  • Akita, Japan
    • Eisai Trial Site #1
  • Aomori, Japan
    • Eisai Trial Site #1
  • Fukui, Japan
    • Eisai Trial Site #1
  • Fukuoka, Japan
    • Eisai Trial Site #1
  • Fukuoka, Japan
    • Eisai Trial Site #2
  • Gifu, Japan
    • Eisai Trial Site #1
  • Hiroshima, Japan
    • Eisai Trial Site #1
  • Hiroshima, Japan
    • Eisai Trial Site #2
  • Kagoshima, Japan
    • Eisai Trial Site #1
  • Kagoshima, Japan
    • Eisai Trial Site #2
  • Kumamoto, Japan
    • Eisai Trial Site #1
  • Kyoto, Japan
    • Eisai Trial Site #1
  • Miyazaki, Japan
    • Eisai Trial Site #1
  • Nara, Japan
    • Eisai Trial Site #1
  • Niigata, Japan
    • Eisai Trial Site #1
  • Okayama, Japan
    • Eisai Trial Site #1
  • Saitama, Japan
    • Eisai Trial Site #1
  • Saitama, Japan
    • Eisai Trial Site #2
  • Shizuoka, Japan
    • Eisai Trial Site #1
  • Shizuoka, Japan
    • Eisai Trial Site #2
  • Toyama, Japan
    • Eisai Trial Site #1
  • Yamagata, Japan
    • Eisai Trial Site #1
  • Aichi
    • Nagoya, Aichi, Japan
      • Eisai Trial Site #1
    • Nagoya, Aichi, Japan
      • Eisai Trial Site #2
    • Nagoya, Aichi, Japan
      • Eisai Trial Site #3
  • Ehime
    • Tōon, Ehime, Japan
      • Eisai Trial Site #1
  • Fukui
    • Yoshida-gun, Fukui, Japan
      • Eisai Trial Site #1
  • Fukuoka
    • Kitakyushu, Fukuoka, Japan
      • Eisai Trial Site #1
    • Koga, Fukuoka, Japan
      • Eisai Trial Site #1
    • Kurume, Fukuoka, Japan
      • Eisai Trial Site #1
  • Hokkaido
    • Sapporo, Hokkaido, Japan
      • Eisai Trial Site #1
    • Sapporo, Hokkaido, Japan
      • Eisai Trial Site #2
  • Hyogo
    • Itami, Hyogo, Japan
      • Eisai Trial Site #1
  • Ibaraki
    • Tsuchiura, Ibaraki, Japan
      • Eisai Trial Site #1
  • Ishikawa
    • Kanazawa, Ishikawa, Japan
      • Eisai Trial Site #1
  • Kagawa
    • Zentsuji, Kagawa, Japan
      • Eisai Trial Site #1
  • Kanagawa
    • Fujisawa, Kanagawa, Japan
      • Eisai Trial Site #1
    • Kawasaki, Kanagawa, Japan
      • Eisai Trial Site #1
  • Kumamoto
    • Goshi, Kumamoto, Japan
      • Eisai Trial Site #1
    • Tamana, Kumamoto, Japan
      • Eisai Trial Site #1
  • Miyagi
    • Iwanuma, Miyagi, Japan
      • Eisai Trial Site #1
    • Sendai, Miyagi, Japan
      • Eisai Trial Site #1
  • Miyazaki
    • Miyakonojo, Miyazaki, Japan
      • Eisai Trial Site #1
  • Nagasaki
    • Omura, Nagasaki, Japan
      • Eisai Trial Site #1
  • Oita
    • Beppu, Oita, Japan
      • Eisai Trial Site #1
  • Okayama
    • Kurashiki, Okayama, Japan
      • Eisai Trial Site #1
  • Osaka
    • Izumi, Osaka, Japan
      • Eisai Trial Site #1
    • Osakasayama, Osaka, Japan
      • Eisai Trial Site #1
    • Sakai, Osaka, Japan
      • Eisai Trial Site #1
    • Sakai, Osaka, Japan
      • Eisai Trial Site #2
    • Takatsuki, Osaka, Japan
      • Eisai Trial Site #1
  • Saitama
    • Asaka, Saitama, Japan
      • Eisai Trial Site #1
    • Higashimurayama, Saitama, Japan
      • Eisai Trial Site #1
  • Shiga
    • Moriyama, Shiga, Japan
      • Eisai Trial Site #1
  • Shimane
    • Matsue, Shimane, Japan
      • Eisai Trial Site #1
  • Shizuoka
    • Hamamatsu, Shizuoka, Japan
      • Eisai Trial Site #1
  • Tokushima
    • Komatsushima, Tokushima, Japan
      • Eisai Trial Site #1
  • Tokyo
    • Kodaira, Tokyo, Japan
      • Eisai Trial Site #1
    • Kokubunji, Tokyo, Japan
      • Eisai Trial Site #1
  • Yamaguchi
    • Ube, Yamaguchi, Japan
      • Eisai Trial Site #1
• Korea, Republic of
  • Busan, Korea, Republic of
    • Facility #1
  • Busan, Korea, Republic of
    • Facility #2
  • Daegu, Korea, Republic of
    • Facility #1
  • Daejeon, Korea, Republic of
    • Facility #1
  • Gwangju, Korea, Republic of
    • Facility #1
  • Incheon, Korea, Republic of
    • Facility #1
  • Seoul, Korea, Republic of
    • Facility #2
  • Seoul, Korea, Republic of
    • Facility #3
  • Seoul, Korea, Republic of
    • Facility #4
  • Seoul, Korea, Republic of
    • Facility #1
  • Seoul, Korea, Republic of
    • Facility #5
  • Seoul, Korea, Republic of
    • Facility #6
  • Seoul, Korea, Republic of
    • Facility #7
  • Seoul, Korea, Republic of
    • Facility #8
• Malaysia
  • Kuala Lumpur, Malaysia
    • Facility #1
  • Perak, Malaysia
    • Facility #1
  • Pulau Pinang, Malaysia
    • Facility #1
  • Terengganu, Malaysia
    • Facility #1
• Taiwan
  • Taichung, Taiwan
    • Facility #1
  • Tainan, Taiwan
    • Facility #1
  • Taipei, Taiwan
    • Facility #1
  • Taipei, Taiwan
    • Facility #2
  • Taoyuan, Taiwan
    • Facility #1
• Thailand
  • Rajathevee, Thailand
    • Facility #1
  • Tha Muang, Thailand
    • Facility #1
  • Tha Muang, Thailand
    • Facility #2
  • Tha Muang, Thailand
    • Facility #3
  • Tha Muang, Thailand
    • Facility #4

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (ADULT, OLDER_ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

1. Male or female and greater than or equal to 12 years of age;
2. Have a diagnosis of epilepsy with partial seizures with or without secondarily generalized seizures
3. Participants with computed tomography (CT) or magnetic resonance imaging (MRI) diagnosis within the last 10 years (for adults) and 5 years (for adolescents) prior to visit 1 that ruled out progressive central nervous system (CNS) disorders, example, neurodegenerative disorders, brain tumors. For participants without existing CT or MRI results, CT or MRI was performed at or after Visit 1 but results evaluation was performed by Visit 2
4. Participants who had been treated for at least 12 weeks but confirmed to be uncontrolled with more than one standard antiepileptic drug (AED) for 2 years before enrollment
5. During the 6-week Prerandomization Phase participants must have had greater than or equal to 5 partial seizures per 6-week
6. Are currently being treated with stable doses and administrations of 1, 2, or a maximum of 3 approved AEDs. Only 1 inducer AED (defined as carbamazepine, phenytoin or oxcarbazepine only) out of the maximum of 3 AEDs is allowed

Exclusion Criteria

1. Presence of nonmotor simple partial seizures only;
2. Presence of primary generalized epilepsies or seizures, such as absences and/or myoclonic epilepsies;
3. Presence or previous history of Lennox-Gastaut syndrome;
4. A history of status epilepticus within 1 year prior to screening
5. Seizure clusters where individual seizures cannot be counted
6. A history of psychogenic seizures within 5 years prior to screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: Placebo	Drug: Placebo; Core study: Week 0 to Week 18 Once daily placebo. Extension study: Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day.
EXPERIMENTAL: Perampanel	Drug: Perampanel; Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day. Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day.; Other Names: E2007

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline)	Seizure frequency was based on number of seizures per 28 days, calculated as the number of seizures over the entire time interval divided by the number of days in the interval and multiplied by 28. All partial seizure included simple partial seizures without motor signs, simple partial with motor signs, complex partial, and complex partial with secondary generalized seizures. A simple partial seizure takes place on one side of the brain. Usually, people experiencing a simple partial seizure do not lose consciousness or awareness. A complex partial seizure is a type of seizure that arises in one lobe of the brain, rather than the whole brain. The seizure affects people's awareness and may cause them to lose consciousness.	Baseline, Week 19

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Core Phase: Responder Rate During the Maintenance Period of the Randomization Phase Relative to the Prerandomization Phase (Baseline)- Last Observation Carried Forward (LOCF)	Responder rate was percentage of participants with greater than or equal to (>=) 50% reduction in seizure frequency during maintenance period of the randomization phase relative to prerandomization phase (baseline). If the reduction in seizure frequency is less than (<) 50%, then the participants are considered as non-responders.	Baseline, Week 19
Core Phase: Percent Change in Seizure Frequency Per 28 Days For Complex Partial Seizures Plus Secondary Generalized Seizures in the Randomization Phase Relative to the Prerandomization Phase (Baseline)	Seizure frequency was based on number of seizures per 28 days, calculated as the number of seizures over the entire time interval divided by the number of days in the interval and multiplied by 28. A complex partial seizure is a type of seizure that arises in one lobe of the brain, rather than the whole brain and it affects awareness and may cause in loss of consciousness. Secondary generalized seizures begin in one part of the brain, but then spread to both sides of the brain.	Baseline, Week 19
Core Phase: Number of Participants With Clinical Global Impression of Change (CGIC) Scores	The investigator evaluated each participant for CGIC questionnaire to assess change in participant's disease clinical status from baseline. Assessment evaluated frequency of seizures, severity of seizures, occurrence of adverse events (AEs), and overall functional status of the participant using the 7-point scale. The evaluation used a 7-point scale with the scores 1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse. Lower score indicated improvement and higher score indicated worsening.	Baseline, Week 19

Collaborators and Investigators

• Sponsor: Eisai Co., Ltd.

Publications and helpful links

General Publications

• Nishida T, Lee SK, Inoue Y, Saeki K, Ishikawa K, Kaneko S. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study. Acta Neurol Scand. 2018 Apr;137(4):392-399. doi: 10.1111/ane.12883. Epub 2017 Dec 17.

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 15, 2012
• Primary Completion (ACTUAL): September 15, 2014
• Study Completion (ACTUAL): May 28, 2020

Study Registration Dates

• First Submitted: June 11, 2012
• First Submitted That Met QC Criteria: June 12, 2012
• First Posted (ESTIMATE): June 13, 2012

Study Record Updates

• Last Update Posted (ACTUAL): July 29, 2021
• Last Update Submitted That Met QC Criteria: July 9, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: epilepsy; seizure; partial seizures; Partial-onset Seizures
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Seizures
• Other Study ID Numbers: E2007-J000-335